Literature DB >> 1350747

The antagonism of benzodiazepine withdrawal effects by the selective cholecystokininB receptor antagonist CI-988.

L Singh1, M J Field, C A Vass, J Hughes, G N Woodruff.   

Abstract

The ability of a selective cholecystokininB (CCKB) receptor antagonist, CI-988, to block benzodiazepine withdrawal effects was examined in mice. The discontinuation of twice daily administration of diazepam (1 mg kg-1, i.p.) induced withdrawal anxiogenesis and a proconvulsant effect. In contrast, no such effects were seen following withdrawal from similar administration of CI-988. However, CI-988 dose-dependently (0.001-1.0 mg kg-1, s.c.) antagonized both the anxiogenesis and the proconvulsant effect following diazepam-withdrawal.

Entities:  

Mesh：

Substances：

Year:  1992        PMID： 1350747      PMCID： PMC1908629          DOI： 10.1111/j.1476-5381.1992.tb14201.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN： 0007-1188            Impact factor:   8.739


  9 in total

1.  Physical dependence induced in DBA/2J mice by benzodiazepine receptor full agonists, but not by the partial agonist Ro 16-6028.

Authors:  J L Moreau; F Jenck; L Pieri; P Schoch; J R Martin; W E Haefely
Journal:  Eur J Pharmacol       Date:  1990-11-06       Impact factor: 4.432

2.  Long-term benzodiazepine treatment reduces neuronal responsiveness to cholecystokinin: an electrophysiological study in the rat.

Authors:  A Bouthillier; C De Montigny
Journal:  Eur J Pharmacol       Date:  1988-06-22       Impact factor: 4.432

3.  Resistance to the anti-anxiety effect of buspirone in patients with a history of benzodiazepine use.

Authors:  E Schweizer; K Rickels; I Lucki
Journal:  N Engl J Med       Date:  1986-03-13       Impact factor: 91.245

4.  The behavioural properties of CI-988, a selective cholecystokininB receptor antagonist.

Authors:  L Singh; M J Field; J Hughes; R Menzies; R J Oles; C A Vass; G N Woodruff
Journal:  Br J Pharmacol       Date:  1991-09       Impact factor: 8.739

5.  Long-term diazepam treatment produces changes in cholecystokinin receptor binding in rat brain.

Authors:  J Harro; A Lang; E Vasar
Journal:  Eur J Pharmacol       Date:  1990-05-03       Impact factor: 4.432

Review 6.  Animal models of drug withdrawal symptoms.

Authors:  M W Emmett-Oglesby; D A Mathis; R T Moon; H Lal
Journal:  Psychopharmacology (Berl)       Date:  1990       Impact factor: 4.530

7.  Development of a class of selective cholecystokinin type B receptor antagonists having potent anxiolytic activity.

Authors:  J Hughes; P Boden; B Costall; A Domeney; E Kelly; D C Horwell; J C Hunter; R D Pinnock; G N Woodruff
Journal:  Proc Natl Acad Sci U S A       Date:  1990-09       Impact factor: 11.205

Review 8.  Buspirone. A preliminary review of its pharmacological properties and therapeutic efficacy as an anxiolytic.

Authors:  K L Goa; A Ward
Journal:  Drugs       Date:  1986-08       Impact factor: 9.546

9.  Evidence for an involvement of the brain cholecystokinin B receptor in anxiety.

Authors:  L Singh; A S Lewis; M J Field; J Hughes; G N Woodruff
Journal:  Proc Natl Acad Sci U S A       Date:  1991-02-15       Impact factor: 11.205
  9 in total
  6 in total

1.  Targeted invalidation of CCK2 receptor gene induces anxiolytic-like action in light-dark exploration, but not in fear conditioning test.

Authors:  Sirli Raud; Jürgen Innos; Urho Abramov; Ain Reimets; Sulev Kõks; Andres Soosaar; Toshimitsu Matsui; Eero Vasar
Journal:  Psychopharmacology (Berl)       Date:  2005-10-14       Impact factor: 4.530

2.  Targeted mutation of CCK2 receptor gene modifies the behavioural effects of diazepam in female mice.

Authors:  Sirli Raud; Kertu Rünkorg; Alar Veraksits; Ain Reimets; Aleksei Nelovkov; Urho Abramov; Toshimitsu Matsui; Michel Bourin; Vallo Volke; Sulev Kõks; Eero Vasar
Journal:  Psychopharmacology (Berl)       Date:  2003-04-23       Impact factor: 4.530

3.  The cholecystokinin-B receptor antagonist CI-988 failed to affect CCK-4 induced symptoms in panic disorder patients.

Authors:  H J van Megen; H G Westenberg; J A den Boer; B Slaap; F van Es-Radhakishun; A C Pande
Journal:  Psychopharmacology (Berl)       Date:  1997-02       Impact factor: 4.530

4.  The benzodiazepine antagonist flumazenil blocks the effects of CCK receptor agonists and antagonists in the elevated plus-maze.

Authors:  P Chopin; M Briley
Journal:  Psychopharmacology (Berl)       Date:  1993       Impact factor: 4.530

5.  Effects of the CCKB antagonist L-365, 260 on benzodiazepine withdrawal-induced hypophagia in rats.

Authors:  A J Goudie; M J Leathley
Journal:  Psychopharmacology (Berl)       Date:  1995-03       Impact factor: 4.530

6.  Effect of CCK receptor antagonists on the antinociceptive, reinforcing and gut motility properties of morphine.

Authors:  L Singh; R J Oles; M J Field; P Atwal; G N Woodruff; J C Hunter
Journal:  Br J Pharmacol       Date:  1996-07       Impact factor: 8.739
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.